4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: Characterization of FHIT and survivin expression and chemopreventive effects of indomethacin

Carcinogenesis

Volumn 26, Issue 3, 2005, Pages 571-578

  Lubet, Ronald A ^a   Huebner, Kay ^b   Fong, Louise Y Y ^b   Altieri, Dario C ^c   Steele, Vernon E ^a   Kopelovich, Levy ^a   Kavanaugh, Claudine ^a   Juliana, M Margaret ^d   Soong, Seng Jaw ^d   Grubbs, Clinton J ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYL(BUTYL)NITROSAMINE; FRAGILE HISTIDINE TRIAD PROTEIN; INDOMETACIN; NITROSAMINE; SURVIVIN; UNCLASSIFIED DRUG; ACID ANHYDRIDE HYDROLASE; CARCINOGEN; MICROTUBULE ASSOCIATED PROTEIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; SURVIVIN PROTEIN, MOUSE; TUMOR PROTEIN;

ARTICLE; BLADDER CANCER; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; METABOLISM;

ACID ANHYDRIDE HYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; IMMUNOHISTOCHEMISTRY; INDOMETHACIN; MALE; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 16244381760     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh352     Document Type: Article

References (28)

1. Grubbs, C.J., Lubet, R.A., Koki, A.T., Leahy, K.M., Masferrer, J.L., Steele, V.E., Kelloff, G.J., Hill, D.L. and Seibert, K. (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine induced urinary bladder cancer in male B6D2F1 mice and female Fischer F-344 rats. Cancer Res., 60, 5599-5602.
2. Becci, P.J., Thompson, H.J., Strum, J.M., Brown, C.C., Sporn, M.B. and Moon, R.C. (1981) N-butyl-N-(4-hydroxybutyl)-nitrosamine induced urinary bladder cancer in C57BL/6xDBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res., 41, 927-932.
3. Grubbs, C.J., Moon, R.C., Squire, R.A., Farrow, G.M., Stinson, S.F., Goodman, D.G., Brown, C.C. and Sporn, M.B. (1977) 13-cis-Retinoic acid: inhibition of bladder cancer induced in rats by N-butyl-N-(4-hydroxybutyl)- nitrosamine. Science, 198, 743-745.
4. Moon, R.C., Kelloff, G.J., Detrisiac, C.J., Steele, V.E., Thomas, K.J. and Sigman, C.J. (1983) Chemoprevention of OH-BBN induced bladder tumors in mice by proxicam. Carcinogenesis, 14, 1487-1490.
5. Okajima, E., Denda, A., Ozono, S., Takahama, M., Akai, H., Sasaki, Y., Kitayama, W., Wakabayashi, K. and Konishi, Y. (1998) Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 specific inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res., 58, 3028-3031.
6. Rao, K.V., Detrisiac, C.J., Steele, V.E., Hawk, E.T., Kelloff, G.J. and McCormick, D.L. (1996) Differential effect of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17, 1435-1438.
7. Ogawa, K., Uzvolgyi, E., St John, M.K., de Olivera, M.L., Arnold, L. and Cohen, S.M. (1998) Frequent P53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice. Mol. Carcinog., 21, 70-79.
8. Yamamoto, S., Chen, T., Murai, T. et al. (1997) Genetic instability and P53 mutations in metastaic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 18, 1877-1882.
9. Marjou, A.E., Delouvee, A., Thiery J.P. and Radvanyi.F. (2000) Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumor progression. Carcinogenesis, 21, 2211-2218.
10. Yao, R., Lemon, W.J., Wang, Y., Grubbs, C.J., Lubet, R.A. and You, M. (2004) Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl (butyl)nitrosamine. Neoplasia, 6, 569-577.
11. Pekarsky, Y., Zanesi, N., Palamarchuk, A., Huebner, K. and Croce, C.M. (2002) FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol, 3, 748-754.
12. Altieri, D.C. (2003) Validating survivin as a cancer therapeutic target. Nature Rev. Cancer, 3, 46-54.
13. Huebner, K. and Croce, C.M. (2003) Cancer and the FRA3B/FHIT locus: it's a hit. Br. J. Cancer, 88, 1501-1506.
14. Ohta, M., Inoue, H., Cotticelli, M.G. et al. (1996) The FHIT gene, spanning the chromosome 3 p fragile site and renal carcinoma-associated t(3:8) breakpoint, is abnormal in digestive tract cancers. Cell, 84, 587-597.
15. Zaneisi, N., Fidanza, V., Fong, L.Y. et al. (2001) The tumor spectrum in FHIT deficient mice. Proc. Natl Acad. Sci. USA, 98, 10250-10255.
16. Altieri, D.C. (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med., 7, 542-547.
17. Sano, H., Kawahito, Y., Wilder, R.L. et al. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55, 3785-3789.
18. Dubinett, S.M., Sharma, S., Huang, M., Dohadwala, M., Pold, M. and Mao, J.T. (2003) Cyclooxygenase-2 in lung cancer. Prog. Exp. Tumor Res., 37, 138-162.
19. Dannenberg, A.J. and Howe, L.R. (2003) The role of COX-2 in breast and cervical cancer. Prog. Exp. Tumor Res., 37, 90-106.
20. Shariat, S.F., Kim, J.H., Ayala, G.E., Kho, K., Wheeler, T.M. and Lerner, S.P. (2003) Cyclooxygenase 2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol., 169, 938-942.
21. Fong, L.Y., Fidanza, V., Zanesi, N. et al. (2000) Muir-Torre link syndrome in FHIT deficient mice. Proc. Natl Acad. Sci. USA, 97, 4742-4747.
22. Skopelitou, A.S., Gloustianou, G., Bai, M. and Huebner, K. (2001) FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo, 15, 169-173.
23. Sozzi, G., Postorino, U., Moiraghi, L. et al. (1998) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res., 58, 5032-5037.
24. Han, S.Y., Iliopoulos, D., Druck, T. et al. (2004) CpG methylation in the Fhit regulatory region: relation to FHIT expression in murine tumors. Oncogens, 23, 3990-3998.
25. Fischer, S.M., Lo, H.H., Gordon, G.B., Siebert, K., Kelloff, G., Lubet, R.A. and Conti, C.J. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase 2 inhibitor and indomethacin against ultra violet light induced skin carcinogenesis. Mol. Carcinog., 25, 231-240.
26. Li, H., Kramer, P.M., Lubet, R.A., Steele, V.E., Kelloff, G.J. and Pereira, M.A. (1999) Termination of piroxicam treatment and the occurrence of azoxymethane induced colon cancer in rats. Cancer Lett., 147, 187-193.
27. Fischer, S.M., Conti, C.J., Viner J., Aldaz, C.M. and Lubet, R.A. (2003) Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV induced skin tumors in mice. Carcinogenesis, 24, 945-952.
28. Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M., Celano, P., Booker, S.V., Robinson, R. and Offerhaus, G.J. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adnomatous polyposis. N. Engl. J. Med., 328, 1313-1316.